NO20083639L - Aurorakinasemodulatorer og fremgangsmate for anvendelse - Google Patents

Aurorakinasemodulatorer og fremgangsmate for anvendelse

Info

Publication number
NO20083639L
NO20083639L NO20083639A NO20083639A NO20083639L NO 20083639 L NO20083639 L NO 20083639L NO 20083639 A NO20083639 A NO 20083639A NO 20083639 A NO20083639 A NO 20083639A NO 20083639 L NO20083639 L NO 20083639L
Authority
NO
Norway
Prior art keywords
compounds
disease states
affecting
modulating
aurora kinase
Prior art date
Application number
NO20083639A
Other languages
English (en)
Norwegian (no)
Inventor
Vinod F Patel
Victor J Cee
Holly L Deak
Bingfan Du
Stephanie D Geuns-Meyer
Brian L Hodous
Hanh Nho Nguyen
Philip R Olivieri
Karina Romero
Laurie Schenkel
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/655,642 external-priority patent/US7560551B2/en
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of NO20083639L publication Critical patent/NO20083639L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/502Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D497/00Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D497/02Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D497/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pyrane Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20083639A 2006-01-23 2008-08-22 Aurorakinasemodulatorer og fremgangsmate for anvendelse NO20083639L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US76167506P 2006-01-23 2006-01-23
US11/655,642 US7560551B2 (en) 2006-01-23 2007-01-18 Aurora kinase modulators and method of use
PCT/US2007/001714 WO2007087276A1 (en) 2006-01-23 2007-01-22 Aurora kinase modulators and method of use

Publications (1)

Publication Number Publication Date
NO20083639L true NO20083639L (no) 2008-10-22

Family

ID=40849087

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20083639A NO20083639L (no) 2006-01-23 2008-08-22 Aurorakinasemodulatorer og fremgangsmate for anvendelse

Country Status (20)

Country Link
EP (1) EP1984353B1 (pt)
JP (2) JP5280862B2 (pt)
KR (2) KR101332975B1 (pt)
AU (2) AU2007208351C1 (pt)
BR (1) BRPI0706684A2 (pt)
CA (1) CA2637658C (pt)
CR (1) CR10213A (pt)
DK (1) DK1984353T3 (pt)
EA (1) EA018128B1 (pt)
ES (1) ES2502790T3 (pt)
GE (1) GEP20125643B (pt)
HR (1) HRP20160039T1 (pt)
HU (1) HUE028504T2 (pt)
IL (1) IL192812A (pt)
MA (1) MA30224B1 (pt)
MY (1) MY161884A (pt)
NO (1) NO20083639L (pt)
NZ (1) NZ569815A (pt)
TN (1) TNSN08310A1 (pt)
WO (1) WO2007087276A1 (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ569815A (en) * 2006-01-23 2011-11-25 Amgen Inc Aurora kinase modulators and method of use
US7776857B2 (en) * 2007-04-05 2010-08-17 Amgen Inc. Aurora kinase modulators and method of use
MX2010010151A (es) * 2008-03-20 2010-10-25 Amgen Inc Moduladores de cinasa aurora y metodo de uso.
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
EP2321298B1 (en) * 2008-08-04 2013-10-02 Amgen Inc. Aurora kinase modulators and methods of use
WO2010019473A1 (en) 2008-08-14 2010-02-18 Amgen Inc. Aurora kinase modulators and methods of use
CA2746307C (en) 2008-12-17 2013-11-19 Amgen Inc. Aminopyridine and carboxypyridine compounds as phosphodiesterase 10 inhibitors
UY32582A (es) 2009-04-28 2010-11-30 Amgen Inc Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero
ES2444777T3 (es) 2009-06-12 2014-02-26 Bristol-Myers Squibb Company Compuestos de nicotinamida útiles como moduladores de quinasas
EA020526B1 (ru) 2009-09-11 2014-11-28 Амген Инк. Применение n-(4-((3-(2-амино-4-пиримидинил)-2-пиридинил)окси)фенил)-4-(4-метил-2-тиенил)-1-фталазинамина для лечения резистентного к антимитотическому агенту рака
EP2688887B1 (en) 2011-03-23 2015-05-13 Amgen Inc. Fused tricyclic dual inhibitors of cdk 4/6 and flt3
MX369738B (es) * 2013-12-03 2019-11-20 Amgen Inc Formas cristalinas de sales de n-(4-((3-(2-amino-4-pirimidinil)-2- piridinil)oxi)fenil)-4-(4-metil-2-tienil)-1-ftalazinamina y usos de las mismas.
JP6483288B2 (ja) 2015-06-03 2019-03-13 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company 心臓血管障害の治療にて用いるための4−ヒドロキシ−3−(ヘテロアリール)ピリジン−2−オン apjアゴニスト
KR20180052635A (ko) 2015-09-18 2018-05-18 가켄 세이야쿠 가부시키가이샤 바이아릴 유도체 및 이를 포함하는 약제
JP7032903B2 (ja) * 2016-10-12 2022-03-09 田辺三菱製薬株式会社 スルホンアミド化合物の製造方法
CN109384782A (zh) * 2017-08-04 2019-02-26 厦门大学 取代五元并六元杂环类化合物、其制备方法、药物组合及其用途
IL273924B2 (en) 2017-10-20 2024-07-01 Univ Vanderbilt Antagonists of the muscarinic acetylcholine receptor m4
WO2020049208A1 (es) 2018-09-09 2020-03-12 Fundacio Privada Institut De Recerca De La Sida - Caixa Aurora cinasa como diana para tratar, prevenir o curar una infección por vih o sida
CA3155864A1 (en) 2019-10-04 2021-04-08 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor m4
CN112898292A (zh) 2019-12-03 2021-06-04 微境生物医药科技(上海)有限公司 新型极光激酶抑制剂及其用途
US11618751B1 (en) 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
CN111302948A (zh) * 2020-04-13 2020-06-19 长兴进源新材料科技有限公司 一种2,2-双(4-氨基苯基)六氟丙烷合成方法
US11319319B1 (en) 2021-04-07 2022-05-03 Ventus Therapeutics U.S., Inc. Compounds for inhibiting NLRP3 and uses thereof
US12331048B2 (en) 2022-10-31 2025-06-17 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors
CN121568926A (zh) * 2023-02-06 2026-02-24 泰普6治疗公司 化合物、组合物及其使用方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU770600B2 (en) * 1999-10-07 2004-02-26 Amgen, Inc. Triazine kinase inhibitors
PL360439A1 (en) 2000-06-28 2004-09-06 Astrazeneca Ab Substituted quinazoline derivatives and their use as inhibitors
US6864255B2 (en) * 2001-04-11 2005-03-08 Amgen Inc. Substituted triazinyl amide derivatives and methods of use
JP4498741B2 (ja) 2001-12-24 2010-07-07 アストラゼネカ アクチボラグ オーロラキナーゼ阻害剤としての置換キナゾリン誘導体
CA2473510A1 (en) * 2002-01-23 2003-07-31 Bayer Pharmaceuticals Corporation Pyrimidine derivatives as rho-kinase inhibitors
AU2003299517A1 (en) 2002-05-23 2004-05-25 Merck & Co., Inc. Mitotic kinesin inhibitors
MY141867A (en) 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
GB0219054D0 (en) 2002-08-15 2002-09-25 Cyclacel Ltd New purine derivatives
WO2004037814A1 (en) 2002-10-25 2004-05-06 Vertex Pharmaceuticals Incorporated Indazolinone compositions useful as kinase inhibitors
FR2853378B1 (fr) 2003-04-02 2006-03-10 Carbone Lorraine Composants Plaquettes de frein a disque ventilees
NZ548128A (en) * 2003-12-29 2010-05-28 Banyu Pharma Co Ltd Novel 2-heteroaryl-substituted benzimidazole derivative
EP1751136B1 (en) * 2004-05-07 2014-07-02 Amgen Inc. Nitrogenated heterocyclic derivatives as protein kinase modulators and use for the treatment of angiogenesis and cancer
NZ569815A (en) * 2006-01-23 2011-11-25 Amgen Inc Aurora kinase modulators and method of use

Also Published As

Publication number Publication date
CR10213A (es) 2008-10-03
GEP20125643B (en) 2012-09-25
KR20110133056A (ko) 2011-12-09
AU2010241280B2 (en) 2013-02-28
KR101300424B1 (ko) 2013-08-26
CA2637658C (en) 2012-07-17
JP5753546B2 (ja) 2015-07-22
EP1984353B1 (en) 2015-12-30
HRP20160039T1 (hr) 2016-02-12
IL192812A0 (en) 2009-02-11
ES2502790T3 (es) 2014-10-06
JP5280862B2 (ja) 2013-09-04
MA30224B1 (fr) 2009-02-02
AU2007208351A1 (en) 2007-08-02
CA2637658A1 (en) 2007-08-02
BRPI0706684A2 (pt) 2011-04-05
DK1984353T3 (en) 2016-03-14
JP2013136585A (ja) 2013-07-11
AU2007208351C1 (en) 2011-07-07
KR20080095889A (ko) 2008-10-29
EP1984353A1 (en) 2008-10-29
HUE028504T2 (en) 2016-12-28
IL192812A (en) 2014-06-30
AU2007208351B2 (en) 2010-08-05
AU2010241280A1 (en) 2010-11-25
JP2009528268A (ja) 2009-08-06
TNSN08310A1 (en) 2009-12-29
WO2007087276A1 (en) 2007-08-02
HK1167140A1 (en) 2012-11-23
MY161884A (en) 2017-05-15
NZ569815A (en) 2011-11-25
KR101332975B1 (ko) 2013-11-25
EA200801732A1 (ru) 2009-02-27
EA018128B1 (ru) 2013-05-30

Similar Documents

Publication Publication Date Title
NO20083639L (no) Aurorakinasemodulatorer og fremgangsmate for anvendelse
MX2009010517A (es) Moduladores de cinasa aurora y metodos de uso.
ATE478861T1 (de) Multizyklische verbindung und verwendungsverfahren
MX2010010151A (es) Moduladores de cinasa aurora y metodo de uso.
MXPA06012613A (es) Derivados heterociclicos nitrogenados como moduladores de proteina cinasa y uso para el tratamiento de angiogenesis y cancer.
MX419368B (es) Heteroarilamidas utiles como inhibidores de kif18a
MX2021007157A (es) Heteroarilamidas utiles como inhibidores de kif18a.
EA200900779A1 (ru) Производные дигидропиридина, полезные как ингибиторы протеинкиназы
NO20070907L (no) Pyrrolo-pyridin kinase modulatorer
EA200970402A1 (ru) Триазолопиридазиновые модуляторы протеинкиназ
NO20083214L (no) Pyrimidinylarylurea-derivater som omdannes til FGF-inhibitorer
WO2009097287A9 (en) Compounds and compositions as kinase inhibitors
NO20084712L (no) Nye farmasoytiske forbindelser
NO20083013L (no) Triazolopyridaziner som tyrosinkinasemodulatorer
NO20070199L (no) Substituerte kinazoloner som anti-kreftmidler
NO20075749L (no) 1H-Quinazoline-2,4-diones and their use as ampa-receptor ligands
NO20071246L (no) Kinazolinonderivater og deres anvendelse som B-RAF-inhibitorer.
NO20061194L (no) Mitotiske kinesininbibitorer
NO20070908L (no) Sammensmeltede ringheterocykelkinasemodulatorer
NO20061743L (no) Kinazolinderivater
TW200638934A (en) Heteroaryl compounds as P2Y1 receptor inhibitors
NO20080168L (no) Aminoquinolin- og aminoquinoazolinkinasemodulatorer
NO20081454L (no) Met-kinaseinhibitorer
NO20062884L (no) AKT-proteinkinaseinhibitorer
NO20091683L (no) Kjemiske forbindelser

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application